Vaccine News and Research

Latest Vaccine News and Research

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

Administration to unveil first national HIV/AIDS strategy today

The White House will unveil the first formal national HIV/AIDS strategy on Tuesday, a plan that aims to reduce the number of new cases by 25 percent in the next five years, officials said. Noting that the number of new infections in the United States has been static -- and that the number of people living with HIV is growing -- the new policy would direct more resources toward African Americans and gay and bisexual men. Latinos and substance abusers should also be a priority, the report says.

14 Jul 2010

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.

14 Jul 2010

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

The "paltry scale of the Pentagon's reconstruction endeavor [in Haiti] -- 1.6 million people displaced and the American military is contributing a few classrooms? -- is emblematic of the international response," columnist Dana Milbank writes in a Washington Post opinion piece.

14 Jul 2010

Anti vaccine group has only a week left to heed to HCCC’s warnings

The New South Wales Health Care Complaints Commission disapproves of the anti vaccination reports from a Bangalow, NSW based Australian Vaccination Network.

13 Jul 2010

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

13 Jul 2010

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.

13 Jul 2010

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has named Case Western Reserve University School of Medicine as the lead institution of an International Center of Excellence for Malaria Research (ICEMR). The $7.9M seven-year grant will accelerate the control of malaria and help eliminate it worldwide.

13 Jul 2010

Wall Street Journal essay examines historical efforts to control malaria

In a Wall Street Journal essay, Sonia Shah, the author of an upcoming book on malaria, outlines the historical efforts to control malaria - from the Roman Empire through today.

13 Jul 2010

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.

12 Jul 2010

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.

12 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy. At a cost of at least $300 for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil- from Merck and Cervarix- from GlaxoSmithKline, are some of the most expensive ever introduced.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Diabetes reform plans do not please the AMA

In a bid to reform the way long term illnesses like diabetes are managed in Australia, the federal government announced a $436 million scheme to be introduced from 2012.

11 Jul 2010

UM researcher uses computer algorithms to develop vaccines for new strains of influenza viruses

Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.

9 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Administration to unveil first national HIV/AIDS strategy today

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

Anti vaccine group has only a week left to heed to HCCC’s warnings

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

Wall Street Journal essay examines historical efforts to control malaria

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Diabetes reform plans do not please the AMA

UM researcher uses computer algorithms to develop vaccines for new strains of influenza viruses

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in